Chong Kun Dang Pharmaceutical (185750) — Capital Reinvestment Ratio
Chong Kun Dang Pharmaceutical (185750) has a Capital Reinvestment Ratio of 6.04x as of March 2026, meaning it reinvests 6% of its operating cash flow (₩12.32 Billion) in capital expenditures (₩74.34 Billion). See Chong Kun Dang Pharmaceutical (185750) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Chong Kun Dang Pharmaceutical Capital Reinvestment Ratio (2016–2025)
This chart tracks Chong Kun Dang Pharmaceutical's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical from 2016 to 2025. For live market cap and broader valuation context, see Chong Kun Dang Pharmaceutical market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.66x | ₩67.36 Billion | ₩179.13 Billion | ▲ +158.6% |
| 2024 | 1.03x | ₩64.29 Billion | ₩66.10 Billion | ▲ +375.4% |
| 2023 | 0.22x | ₩318.16 Billion | ₩68.81 Billion | ▼ -67.4% |
| 2022 | 0.66x | ₩67.73 Billion | ₩44.90 Billion | ▼ -82.3% |
| 2021 | 3.74x | ₩12.90 Billion | ₩48.24 Billion | ▲ +1095.0% |
| 2020 | 0.31x | ₩104.32 Billion | ₩32.64 Billion | ▲ +10.7% |
| 2019 | 0.28x | ₩77.29 Billion | ₩21.84 Billion | ▼ -45.0% |
| 2018 | 0.51x | ₩42.63 Billion | ₩21.92 Billion | ▲ +112.2% |
| 2017 | 0.24x | ₩81.67 Billion | ₩19.79 Billion | ▼ -64.5% |
| 2016 | 0.68x | ₩57.79 Billion | ₩39.44 Billion | — |